Overview

A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This was an open-label, multicenter, single-arm, Phase II trial of bevacizumab combined with first- or second-line therapy in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with previously treated central nervous system (CNS) metastases. A total of 115 patients enrolled in the study.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Bevacizumab